Clinical variables alone had limited predictive value, supporting the need for molecular and immune biomarkers to better identify this subgroup of patients with HER2-positive metastatic breast cancer.
T. Grinda, M. Carton, S. Morganti et al.· Breast· 0 citations
These real-world data suggest limited long-term efficacy of chemotherapy-based treatments for patients with ET-resistant HER2-low, HR-positive metastatic breast cancer, emphasizing high unmet need in this population.
W. Jacot, P. Macouillard, Su-Yuan Zhang et al.· Breast· 0 citations
Trastuzumab deruxtecan (T-DXd) is the current standard second-line therapy for human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC), and it has been recently approved by FDA as first line therapy in combination with pertuzumab, following the results of the DESTINY-Breast09 trial. Howe...
J. Frenel, A. de Nonnevile, C. Guérin-Charbonnel et al.· Breast· 0 citations
The model generated treatment-specific recurrence probabilities for each patient, with near-perfect calibration and strong prognostic discrimination across both 5- and 10-year follow-up horizons, and out-performed existing recurrence-score-based tests.
D. Biswas, Jeroen Berrevoets, A. McClean et al.· 3 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.